Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combinations versus daratumumab, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON53729Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of talquetamab, daratumumab, pomalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-Free Survival. Started Mar 2023; status: recruiting.
02
Drugs
talquetamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53729.